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Abstract
Prolonged parenteral nutrition (PN) leads to liver da-
mage. Recent interest has focused on the lipid component 
of PN. A lipid emulsion based on w-3 fatty acids decrea-
se conjugated bilirubin. A mixed lipid emulsion derived 
from soybean, coconut, olive, and fish oils reverses jaun-
dice. 
Here we report the reversal of cholestasis and the im-
provement of enteral feeding tolerance in 1 infant with 
intestinal failure-associated liver disease. Treatment in-
volved the substitution of a mixed lipid emulsion with one 
containing primarily omega-3 fatty acids during 37 days. 
Growth and biochemical tests of liver function improved 
significantly. This suggests that fat emulsions made from 
fish oils may be more effective means of treating this 
condition compared with an intravenous lipid emulsion 
containing soybean oil, medium -chain triglycerides, oli-
ve oil, and fish oil.
(Nutr Hosp. 2015;31:514-516)
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UNA EmUlSIóN lIPíDICA bASADA 
ExClUSIvAmENTE EN ACEITE DE PESCADO 
REvIERTE lA COlESTASIS
Resumen
la nutrición parenteral prolongada produce daño he-
pático. Recientemente se ha comunicado el efecto de las 
emulsiones lipídicas intravenosas basadas exclusivamen-
te en ácidos grasos omega-3 en la resolución de la coles-
tasis. lo mismo se ha observado con el uso de emulsiones 
lipídicas mixta derivadas del aceite de soja, coco, oliva y 
pescado.
Comunicamos la desaparición de colestasis y mejo-
ría de la tolerancia enteral en un niño con enfermedad 
hepática asociada a nutrición parenteral. El tratamien-
to consistió en sustituir una emulsión lipídica mixta por 
otra que contenía de forma exclusiva aceite de pescado 
durante 37 días. El crecimiento y los datos bioquímicos 
de función hepática mejoraron de forma significativa. 
Este caso sugiere que emulsiones lipídicas intravenosas a 
partir de aceite de pescado pueden ser mas eficaces para 
tratar la colestasis si se comparan con emulsiones mixtas.
(Nutr Hosp. 2015;31:514-516)
DOI:10.3305/nh.2015.31.1.8284
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Introduction
Parenteral nutrition (PN) is a live-saving nutritional 
support for premature and low-birth weight infants and 
other hospitalized infants. A challenge in the care of 
premature infants is to provide sufficient nutrition to 
meet their high metabolic needs for growth, but ag-
gressive administration of PN increases the risk for 
metabolic liver disease. Intestinal failure-associated 
liver disease (IFALD), previously named PN-associat-
ed liver disease (PNALD), is one of the main compli-
cations of long-term PN. 
Although reports of its incidence and severity 
vary, estimates suggest that approximately 10-30% 
of patients who receive PN will develop cholestasis 
and 40-60% of neonates with significant cholestasis 
who cannot tolerate enteral nutrition can eventually 
lead to end-stage liver disease and need for trans-
plant1. 
The etiology of IFALD is multifactorial; risk factors 
include prematurity, birth weight, sepsis, the initial 
illness and the absence of enterohepatic circulation. 
In the last years, there has been much interest in the 
role that the dose and composition of intravenous fat-
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ty acid emulsions may play in the physiopathology of 
IFALD2.
Traditionally used soy based lipid emulsions (Intr-
alipid®) are enriched with the fatty acids linoleic acid 
(n-6, 53%) and are also enriched with phytosterols, 
which are cholesterol-like molecules derived from 
soybeans. Several newer parenteral lipid emulsions 
have been developed in the past 10 to 15 years con-
taining single source lipid or blends of lipids; these 
more recently developed lipid emulsions have been 
termed “new generation”. New generation parenteral 
lipid emulsions containing pure olive oil (Clinole-
ic®), pure fish oil (Omegaven®), or various blends 
of soy, olive, medium chain triglyceride, and fish oil 
(Lipofundin®, SMOFlipid®, Lipoplus®) have been ap-
proved in Europe. 
Recent studies have demonstrated resolution of 
cholestasis in patients with IFALD using an intra-
venous lipid emulsion composed entirely of fish oil, 
commercially available as Omegaven® 10% (Frese-
nius Kabi, Hamburg, Germany)3. European studies 
have also demonstrated that mixed fatty acid emul-
sions, such as SMOF® (15% fish oil, 30% soybean oil) 
(Fresenius Kabi, Hamburg, Germany) resolve paren-
teral nutrition-associated jaundice4.
We present one of the first patients treated with 
Omegaven in Spain and the first one we know that re-
versed cholestasis with Omegaven® after being treated 
with SMOF®.
Case report
Patient is a male born at 31+2 weeks’ gestation, who 
suffered gastroschisis. He was admitted in our hospital 
at 9 days of life after intestinal resection. The intestine, 
from 15 cm distal to pylorus to the distal descending 
colon was lost, which left 15 cm of small intestine 7 
cm of sigmoid colon. He received total PN since birth. 
At admission, we started trophic feedings that had 
to be stopped at 16 days of life because of nosoco-
mial sepsis by Klebsiella oxytoca. At the same time, 
he presented a progressive increase of bilirubin, up to 
15,7mg/dl direct bilirubin (21,4mg/dl total bilirubin). 
They gradually lower, but after sepsis resolution, still 
persisted hyperbilirubinaemia and intractable feeding 
difficulties. At best, he tolerated only administration 
10 cc/kg/day. His PN regimen included parenteral lip-
id emulsions (SMOF® 20%; Fresenius Kabi, Hamburg, 
Germany) at a dose of 2.8 g/kg per d. In light of the 
laboratory findings, total bilirubin of 5.2mg/dl and di-
rect bilirubin of 4.1mg/dl, an alternative intravenous 
fat emulsion was considered. The infant was given the 
omega-3 based emulsion Omegaven® (Fresenius Kabi, 
Hamburg, Germany) at a dose of 1g/kg/day. Informed 
consent from the infant’s parents was obtained. Moni-
toring included the assessment at frequent intervals of 
serum elctrolytes, complete blood counts, serum try-
glycerides, blood glucose and liver enzymes including 
aspartate amino transferase (AST) and amino alanine 
transferase (ALT).
The AST and ALT concentrations normalized. 
Cholestasis, defined as a direct bilirubin concentration 
> 2mg/dL, resolved within 24 days despite the con-
tinuing PN requirement. After initiation of therapy 
with Omegaven®, our patient presents an improvement 
in enteral tolerance, up to 85cc/kg/day 35 days after 
initiation of Omegaven®. Therapy with Omegaven® is 
stopped after 37 days, with transaminases and biliru-
bin in normal values. The patient did not suffer any 
complication related to Omegaven® administration, 
the levels of triglycerides remain in the normal limits 
(99 mg/dl) and he showed gain in weight, length and 
head circumference. 
Discussion
The etiology of IFALD, one of the main complica-
tions of long-term PN, remains unclear. A number of 
causes of IFALD have been proposed. Recent studies 
have implicated the use of soy based lipid emulsions in 
the etiology of IFALD. Phytosterols are found in soy-
bean oil. Phytosterols are known to impair bile flow 
and enhance steatosis contributing to hepatic injury2. 
Soybean oil is composed mainly of omega-6 fatty 
acids, which produce a cascade of pro-inflammatory 
compounds2. 
Different studies have demonstrated that when 1g/
kg/day of exclusive fish oil is used benefits cholesta-
sis resolutions and reestablishment of enteral nu-
trition. Fish-oil contains mainly anti-inflammatory 
omega-3 fatty acids and has higher level of alfa to-
choferol. High omega-6:omega-3 fatty acids ratios 
also affect lipid metabolism by regulating fat storage. 
As fat accumulates in hepatic cells results in hepatic 
injury. 
SMOF®, being a mixed emulsion (30% soybean, 
30% MCT, 25% olive oil, 15% fish oil), would have 
intermediate results between Omegaven® e Intralip-
id®, as it has been shown in animal models5. Differ-
ent authors have compared SMOF® with Intralipid®, 
proving that SMOF® reduces total and conjugated 
bilirubin levels. That suggests that a reduction in 
the proportion of soy-based lipids could reduce bil-
irubin. There are any human studies that compare 
SMOF® and Omegaven® but the animal models sug-
gest that even small amounts of soy plant based lipid 
emulsions could contribute to hepatic injury. That 
is why, in certain cases, such as our patient, the ad-
ministration of a 100% fish oil emulsion could be 
beneficial 
Omegaven® is administrated at a dose of 1g/kg/day. 
Some authors associated its benefit to the reduction of 
lipid provision6. However, Nehra et al7 have recently 
shown that neonates receiving soybean oil-based lipid 
emulsion at 1g/kg/d and those receiving the lipid emul-
sion at 2-3g/kg/d did not differ in cholestasis grade. 
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Although the reduction in lipid provision (1g/
kg/d) and the increase in the amount of carbohy-
drates to provide adequate calories, would suppose 
an increment in lipogenesis and a theoretical essen-
tial fatty acid deficit, that has not been described; 
there has not been found either a growth delay in 
patients treated with Omegaven®8. On the other side, 
reduction of soy based lipid emulsions to 1g/k/d 
could lead to a essential fatty acid deficit9. There are 
no data about the effect of lipid reduction on neuro-
logic development. 
Sepsis was a confounding factor in our patient, as 
with its resolution bilirubin level was reduced; how-
ever, with Omegaven® administration, not only biliru-
bin was reduced but also made possible enteral feed-
ing tolerance, up to 100cc/kg./d, with normal growth. 
Reestablishment of enteral feeding has been already 
described by other authors10 and could be due to the 
anti-inflammatory properties of omega-3 fatty acids 
and alpha tocopherol. 
Although the improvement and even resolution 
of cholestasis with Omegaven® has been reported in 
many publications, that may not reflect a similar his-
tologic regression, as has been already pointed out11. 
In addition, all the studies are directed to the treatment 
of an advanced grade of hepatic damage and is still 
unknown if Omegaven® could be also useful in the pre-
vention of IFALD. 
We conclude that this brief report describes that 
administration of exclusively fish oil-based emul-
sions resolved cholestasis. This therapy may offer 
a potential solution when mixed emulsions do not 
revert cholestasis. More studies are needed to know 
the exact mechanism by which omega-3 fatty acids 
help to reestablish enteral feeding. A randomized, 
controlled trial is necessary to determine the efficacy 
of an exclusively fish oil-based emulsion compared 
with a mixed lipid emulsion in the treatment of IF-
ALD. 
References
1. Lauriti G, Zani A, Aufieri R, Cananzi M, Chiesa PL, Eaton 
S, Pierro A. Incidence, prevention, and treatment of paren-
teral nutrition-associated cholestasis and intestinal failure-as-
sociated liver disease in infants and children: a systematic 
review. JPEN J Parenter Enteral Nutr. 2014; 38:70-85. doi: 
10.1177/0148607113496280.
2. Calkins KL, Venick RS, Devaskar SU. Complications associ-
ated with parenteral nutrition in the neonate. Clin Perinatol. 
2014; 41:331-45. doi: 10.1016/j.clp.2014.02.006.
3. Burrin DG, Ng K, Stoll B, De Pipaón MS. Impact of new-gen-
eration lipid emulsions on cellular mechanisms of parenteral 
nutrition-associated liver disease. Adv Nutr. 2014; 5:82-91. doi: 
10.3945/an.113.004796.
4. Muhammed R, Bremner R, Protheroe S, Johnson T, Holden 
C, Murphy MS. Resolution of parenteral nutrition-associated 
jaundice on changing from a soybean oil emulsion to a com-
plex mixed-lipid emulsion. J Pediatr Gastroenterol Nutr 2012; 
54:797-802.
5. Meisel JA, Le HD, de Meijer VE, Nose V, Gura KM, Mulkern 
RV, Akhavan Sharif MR, Puder M. Comparison of 5 intrave-
nous lipid emulsions and their effects on hepatic steatosis in a 
murine model. J Pediatr Surg 2011; 46: 666-73.
6. Colomb V, Jobert-Girauld A, Lacaille F, Goulet O, Fournet 
JC, Ricour C. Role of lipid emulsions in cholestasis associated 
with long-term parenteral nutrition in children. J Parenter En-
teral Nutr 2000; 24:345-350.
7. Nehra D, Fallon EM, Carlson SJ, Potemkin AK, Hevelone ND, 
Mitchell PD, Gura KM, Puder M. Provision of a soy-based in-
travenous lipid emulsion at 1g/kg/d does not prevent cholestasis 
in neonates. JPEN J Parenter Enteral Nutr 2013; 37:498-505.
8. Fallon EM, Le HD, Puder M. Prevention of parenteral nu-
trición-associated liver disease: role of omega-3 fish oil. Curr 
Opin Organ Transplant 2010; 15:334-340.
9. Cober MP, Killu G, Brattain A, Welch KB, Kunisaki SM, Te-
itelbaum DH. Intravenous fat emulsions reduction for patients 
with parenteral nutrition associated liver disease. J Pediatr 
2012; 160:421-7.
10. Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW. 
Changing the paradigm: omegaven for the treatment of liver 
failure in pediatric short bowel syndrome. J Pediatr Gastroen-
terol Nutr 2009; 48:209-15.
11. Mercer DF, Hobson BD, Fischer RT, Talmon GA, Perry DA, 
Gerhardt BK, Grant WJ, Botha JF, Langnas AN, Quiros-Tejeira 
RE. Hepatic fibrosis persists and progresses despite biochem-
ical improvement in children treated with intravenous fish oil 
emulsion. J Pediatr Gastroenterol Nutr 2013; 56:364-9.
060_8284 Una emulsión lipídica basada exclusivamente en aceite de pescado.indd   516 30/12/14   00:51
